Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MUHAMMAD M ALAM

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1417906835
CMS profile
18470
Location
FRESNO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$5,095.85

184 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,937.23 175
Consulting Fee $525.00 1
Long term medical supply or device loan $498.50 5
Education $135.12 3

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $861.47 15
Novartis Pharmaceuticals Corporation $859.67 20
PFIZER INC. $243.37 12
Boehringer Ingelheim Pharmaceuticals, Inc. $218.60 5
Takeda Pharmaceuticals U.S.A., Inc. $210.70 15
Merck Sharp & Dohme LLC $201.68 10
GlaxoSmithKline, LLC. $197.74 10
Daiichi Sankyo Inc. $183.55 11
Janssen Biotech, Inc. $171.07 6
E.R. Squibb & Sons, L.L.C. $149.68 11
Astellas Pharma US Inc $136.82 6
Novo Nordisk Inc $124.85 1
Exelixis Inc. $120.43 4
ABBVIE INC. $92.64 4
Lilly USA, LLC $87.69 4
Incyte Corporation $83.99 1
Eisai Inc. $75.39 3
Regeneron Healthcare Solutions, Inc. $74.11 2
Genentech USA, Inc. $68.06 3
Celgene Corporation $66.35 4
BeiGene USA, Inc. $65.65 4
ARRAY BIOPHARMA INC $61.65 3
Gilead Sciences, Inc. $54.68 2
Stemline Therapeutics Inc. $48.53 1
TAIHO ONCOLOGY, INC. $48.29 2
Aveo Pharmaceuticals, Inc. $47.18 2
Sumitomo Pharma America, Inc. $40.02 2
Apellis Pharmaceuticals, Inc. $38.19 2
Ipsen Biopharmaceuticals, Inc $37.88 2
PharmaEssentia USA Corporation $37.03 2
Myriad Genetic Laboratories, Inc. $37.01 1
Octapharma USA, Inc. $35.31 2
Medtronic, Inc. $35.25 1
Immunocore Limited $34.44 1
SpringWorks Therapeutics, Inc. $32.83 1
Rigel Pharmaceuticals, Inc. $25.88 1
Tempus AI, Inc $25.05 1
Geron Corporation $24.91 1
ACCORD HEALTHCARE, INC. $24.29 1
SERVIER PHARMACEUTICALS LLC $24.05 1
GENZYME CORPORATION $23.74 1
Agios Pharmaceuticals, Inc. $23.50 1
BioMarin Pharmaceutical Inc. $22.59 1
Deciphera Pharmaceuticals Inc. $20.04 1

Page 4 of 4; records 151–184 of 184 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MUHAMMAD M ALAM

NPI 1417906835 · CMS profile ID 18470

Allopathic & Osteopathic Physicians / Internal Medicine

FRESNO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–184 of 184 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417906835?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MUHAMMAD M ALAM, NPI 1417906835, CMS profile ID 18470. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–184 of 184 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417906835?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MUHAMMAD M ALAM, NPI 1417906835, CMS profile ID 18470. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–184 of 184 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417906835?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MUHAMMAD M ALAM, NPI 1417906835, CMS profile ID 18470, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–184 of 184 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1417906835?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

184 matching records · $5,095.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 184 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–184 of 184.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Tempus AI, Inc $25.0503/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150160010 CMS
Exelixis Inc. $20.0403/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138562500 CMS
Astellas Pharma US Inc $25.3903/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139266204 CMS
E.R. Squibb & Sons, L.L.C. $17.4703/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101576282 CMS
Novartis Pharmaceuticals Corporation $23.6003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086707273 CMS
BeiGene USA, Inc. $16.7603/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120859227 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.4102/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118001701 CMS
Takeda Pharmaceuticals U.S.A., Inc. $8.4602/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144952435 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.0802/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144952437 CMS
PFIZER INC. $33.7002/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131467542 CMS
Octapharma USA, Inc. $18.4702/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142312245 CMS
Merck Sharp & Dohme LLC $25.5502/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141738063 CMS
Genentech USA, Inc. $25.9102/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133076505 CMS
Merck Sharp & Dohme LLC $9.0002/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141738061 CMS
E.R. Squibb & Sons, L.L.C. $18.6602/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101576259 CMS
Daiichi Sankyo Inc. $8.2702/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089391998 CMS
AstraZeneca Pharmaceuticals LP $22.3001/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104205259 CMS
PFIZER INC. $12.5101/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131442531 CMS
PFIZER INC. $1.1401/30/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131445414 CMS
PFIZER INC. $29.5501/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131461810 CMS
Eisai Inc. $23.9701/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110768365 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7.2301/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144952431 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.3701/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144952433 CMS
Novartis Pharmaceuticals Corporation $21.9701/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086707271 CMS
Daiichi Sankyo Inc. $17.1801/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089391996 CMS
Merck Sharp & Dohme LLC $27.0701/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141737899 CMS
Aveo Pharmaceuticals, Inc. $22.4201/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143483021 CMS
PFIZER INC. $21.5301/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131448976 CMS
BioMarin Pharmaceutical Inc. $22.5901/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127059849 CMS
Lilly USA, LLC $18.7501/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135227365 CMS
GlaxoSmithKline, LLC. $26.6801/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116339341 CMS
Astellas Pharma US Inc $23.0901/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139312258 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.2401/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118001705 CMS
ABBVIE INC. $21.4001/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195836 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $67,742.05 342
PY2020 $14,979.05 51
PY2021 $344.67 14
PY2022 $6,734.96 32
PY2023 $10,516.57 66
PY2024 $5,095.85 184
PY2025 $8,618.95 200

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $44,235.38 30

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $135.76 11/19/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220772785
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 11/19/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220772787
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 11/19/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220772789
Principal investigator 1 Boehringer Ingelheim International GmbH $1,227.60 11/19/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220772791
Principal investigator 1 Boehringer Ingelheim International GmbH $18.56 11/19/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220772793
Principal investigator 1 Boehringer Ingelheim International GmbH $285.60 11/19/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220772795
Principal investigator 1 Boehringer Ingelheim International GmbH $31.62 11/19/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220772797
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,500.00 10/10/2025 Non-covered Recipient Entity
ClinR?? Inc.
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220814999
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,500.00 10/10/2025 Non-covered Recipient Entity
ClinR?? Inc.
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220815001
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,000.00 10/10/2025 Non-covered Recipient Entity
ClinR?? Inc.
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220815003
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,275.00 10/10/2025 Non-covered Recipient Entity
ClinR?? Inc.
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220815005
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 10/10/2025 Non-covered Recipient Entity
ClinR?? Inc.
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220815007
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,030.00 10/10/2025 Non-covered Recipient Entity
ClinR?? Inc.
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220815009
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,000.00 10/10/2025 Non-covered Recipient Entity
ClinR?? Inc.
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220815011
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,000.00 10/10/2025 Non-covered Recipient Entity
ClinR?? Inc.
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220815013
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,500.00 10/10/2025 Non-covered Recipient Entity
ClinR?? Inc.
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220815015
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $746.68 06/24/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998547
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $23.32 06/24/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998549
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $219.78 06/24/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998551
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $219.00 06/24/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998553
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $37.44 06/24/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998555
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $7.98 06/24/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998557
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $24.82 06/24/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998559
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $746.68 02/25/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998533
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $23.32 02/25/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998535
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $219.78 02/25/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998537
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $219.00 02/25/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998539
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $37.44 02/25/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998541
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $7.98 02/25/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998543
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $24.82 02/25/2025 Non-covered Recipient Entity
Premier Cancer Care And Infusion Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998545